The CBLL1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the CBLL1 gene in the A-549 human lung adenocarcinoma cell line. This product provides a heterogeneous pool of gene-edited cells with loss-of-function mutations in CBLL1, enabling researchers to investigate the biological functions of the encoded Hakai protein in a cancer-relevant context without the constraints of clonal selection. The polyclonal format captures the diversity of editing outcomes, offering a robust and efficient model for studying gene disruption phenotypes in bulk cell populations.
The A-549 cell line is an adherent epithelial cell line originally derived from a 58-year-old Caucasian male with lung carcinoma. These cells are widely employed as a model system for lung adenocarcinoma, drug metabolism studies, and cancer biology research. Their epithelial origin and well-characterized genetic background make them particularly suitable for examining pathways governing cell adhesion, migration, and epithelial-mesenchymal transition (EMT). The stable, adherent nature of A-549 cells facilitates a broad range of functional assays, including imaging-based analyses of junctional integrity and quantitative motility measurements.
CBLL1 encodes Hakai, an E3 ubiquitin ligase that specifically ubiquitinates E-cadherin upon phosphorylation by Src kinase, targeting it for proteasomal degradation. This activity disrupts adherens junctions, liberates ??-catenin from the membrane complex, and promotes its nuclear translocation, where it coactivates transcription factors such as TCF/LEF to drive expression of EMT-associated genes including Snail, Slug, and Twist. The CBLL1/Hakai pathway is activated downstream of receptor tyrosine kinase signaling by ligands such as epidermal growth factor (EGF), hepatocyte growth factor (HGF), and transforming growth factor-?? (TGF-??), and it functions in concert with other adaptor proteins such as Cbl and adherens junction components. By removing E-cadherin, Hakai destabilizes cell?Ccell contacts and enables the morphological and behavioral changes characteristic of the EMT program.
Disruption of CBLL1 in A-549 cells creates a valuable loss-of-function model for dissecting the role of Hakai-mediated E-cadherin turnover in lung adenocarcinoma progression. Given that A-549 cells express E-cadherin and are known for their partial mesenchymal features, knockout of CBLL1 is expected to stabilize E-cadherin, reinforce adherens junctions, and reduce the migratory and invasive potential typically associated with EMT. This engineered system allows for precise evaluation of how Hakai influences cell adhesion, ??-catenin signaling, and the ubiquitin-proteasome system within a carcinoma-derived epithelial context. The polyclonal nature ensures that downstream phenotypic assessments are not skewed by clonal artifacts, providing biologically representative data on CBLL1 function.
Researchers can employ these CBLL1 knockout A-549 polyclonal cells in a wide array of experimental setups. Typical applications include Western blotting and immunofluorescence to monitor E-cadherin expression and localization, Transwell migration and invasion assays to assess metastatic behavior, and co-immunoprecipitation experiments to verify Hakai?CE-cadherin interactions. Ubiquitination assays can directly measure changes in E-cadherin modification, while RT-qPCR can profile alterations in EMT transcription factor expression. Wound healing assays further enable quantitative analysis of collective cell migration. These cells are also ideal for drug screening campaigns aimed at identifying anti-metastatic compounds that modulate the Hakai/E-cadherin axis. For additional information or customized inquiries, please contact Ascent Research.
